Enanta Pharmaceuticals (ENTA) Assets Average (2013 - 2026)

Enanta Pharmaceuticals (ENTA) has 14 years of Assets Average data on file, last reported at $322.1 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 4.08% year-over-year to $322.1 million; the trailing twelve-month figure through Mar 2026 stood at $322.1 million (down 4.08% YoY), and the FY2025 full-year result was $328.7 million, down 21.64% from the prior year.
• Assets Average for Q1 2026 stood at $322.1 million, up from $305.1 million in the prior quarter.
• Across five years, Assets Average topped out at $478.7 million in Q3 2023 and bottomed at $290.9 million in Q3 2025.
• The 5-year median for Assets Average is $380.3 million (2022), against an average of $375.1 million.
• The widest annual swing landed in 2023, when Assets Average climbed 25.88%; it then declined 24.98% in 2025.
• A 5-year view of Assets Average shows it stood at $361.5 million in 2022, then gained by 23.21% to $445.4 million in 2023, then decreased by 18.58% to $362.6 million in 2024, then retreated by 15.86% to $305.1 million in 2025, then advanced by 5.57% to $322.1 million in 2026.
• The last three Assets Average figures came in at $322.1 million (Q1 2026), $305.1 million (Q4 2025), and $290.9 million (Q3 2025), per Business Quant data.

Peer Comparison